Curative Hep C Treatment Benefits Non-Liver Health and Survival in HIV For people living with both HIV and hepatitis C virus (HCV), not only does curative hepatitis C treatment reduce the risk of liver-related disease and death, but it also helps limit HIV disease progression and deaths not related to liver disease, according to a Spanish study published ahead of print by Clinical Infectious Diseases.
May 30, 2012
FDA Turns Down Prezista 800 mg Tablet
The U.S. Food and Drug Administration has not approved Janssen Therapeutics’ application to market an 800 milligram (mg) tablet version of its protease inhibitor Prezista (darunavir), The Associated Press reports.
May 29, 2012
Adherence Challenges in Intermittent HIV PrEP Study
Intermittent use of Truvada (tenofovir plus emtricitabine) as pre-exposure prophylaxis was associated with poor adherence, compared with daily use of the tablet to prevent HIV infection, according to results of a small clinical trial published in the online scientific journal PLoS ONE.
May 25, 2012
HIV Treatment Reduces Incidence, Improves Regression, of Cervical HPV Lesions Not only did antiretroviral therapy reduce the incidence of new human papillomavirus (HPV)-associated precancerous cervical lesions in a study of South African women living with HIV, it was also linked to the regression of lesions detected before treatment was started, according to an encouraging paper published online ahead of print by the journal AIDS.
May 23, 2012
Sperm Washing Fertility Treatment Not Necessary: U.K. HIV Draft Guidelines
Sperm washing—an effective but costly fertility treatment for HIV-serodiscordant couples—may no longer be necessary, at least in the United Kingdom, under certain circumstances, according to draft guidelines from the National Institute for Health and Clinical Excellence (NICE) summarized by aidsmap.
May 22, 2012
Rectal Microbicide Shows Better Safety in Laboratory Study Laboratory testing of a modified version of the Viread (tenofovir) microbicide gel provides further evidence that it may be safe for rectal use, according to a paper published online ahead of print by the Journal of Antimicrobial Chemotherapy.
Hep C Risk Highest for Baby Boomers, but Most Haven’t Been Tested Almost three-quarters of those most likely to be living with chronic hepatitis C virus (HCV) infection—baby boomers, notably those born between 1945 and 1965—have never been tested or are unsure if they have been tested for hepatitis C, according to a new survey conducted by the American Gastroenterological Association (AGA).
May 17, 2012
Study Raises Sudden Cardiac Death Concerns in People With HIV Sudden cardiac death—when death occurs within a very short period of time after the onset of heart attack symptoms—accounted for most of the cardiac and non-AIDS natural deaths seen in a chart review of people living with HIV receiving care at San Francisco General Hospital (SFGH), according to a new report published May 15 in the Journal of the American College of Cardiology.
May 16, 2012
PEPFAR Works: Hundreds of Thousands of African Lives Saved
The U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) saved more than 740,000 African lives between 2004 and 2008, according to a new report published in the May 16 issue of The Journal of the American Medical Association (JAMA).
May 15, 2012
Orasure In-Home HIV Test Gets Unanimous Approval Recommendation
Orasure’s oral swab-based rapid in-home HIV test has been recommended for approval by the U.S. Food and Drug Administration’s Blood Products Advisory Committee. If the FDA follows its advisory committee’s recommendation, the OraQuick In-Home HIV Test will be the first complete screening assay for purchase over-the-counter (OTC) from pharmacies and internet retailers.
May 14, 2012
National Hispanic Hepatitis Awareness Day is May 15 Tuesday, May 15, marks the debut of the annual National Hispanic Hepatitis Awareness Day. Coordinated by the Latino Commission on AIDS, this important series of events, primarily focusing on the need for increased screening and testing in Latino communities, will take place annually on May 15 and will coincide with viral hepatitis testing and educational programming during National Hepatitis Awareness month.
May 11, 2012
Truvada Receives PrEP Approval Recommendation
In a series of votes by the U.S. Food and Drug Administration’s Antiviral Drugs Advisory Committee, Truvada (tenofovir plus emtricitabine) has been recommended for approval as the first prescription drug to prevent HIV among those at risk for the infection.
Gilead Quad Tablet Gets FDA Committee Approval Nod
An advisory committee to the U.S. Food and Drug Administration (FDA) has voted 13 to 1 in support of approval of Gilead’s “Quad,” the unofficial name for a fixed-dose combination tablet containing the elvitegravir, cobicistat, Viread (tenofovir) and Emtriva (emtricitabine). Should the FDA follow the recommendation of its Antiviral Drugs Advisory Committee, which met at the DoubleTree Hotel in Silver Spring on May 11, the drug will be the third all-in-one regimen to be approved by the agency.
May 09, 2012
Depression Is Common and Needs Managing Before and During Hep C Interferon Treatment Monitoring people undergoing therapy for hepatitis C virus (HCV) infection for depression, and taking steps to manage this common side effect of pegylated interferon-based treatment, is an essential component of care, according to a new review article published by the International Journal of Interferon, Cytokine and Mediator Research.
May 08, 2012
Risk of Liver-Related Deaths Twice as High With Chronic Hep B Versus Hep C In a cohort of men who have sex with men, most of whom were living with HIV, those who were coinfected with chronic hepatitis B virus (HBV) were twice as likely to die of liver disease compared with those chronically infected with hepatitis C virus (HCV), according to a new report published online ahead of print by Clinical Infectious Diseases.
May 03, 2012
Gene-Modified T Cells Persist for a Decade, Without Major Risks, in HIV Studies
Genetically modified T cells—notably CD4 and CD8 cells—administered to people living with HIV participating in one of three clinical trials conducted between 1998 and 2002 are detectable more than a decade later, suggesting that single infusions of cells altered to target or block HIV have the potential for long-term efficacy. According to the paper, published in the May 2 issue of Science Translational Medicine and summarized in a University of Pennsylvania news release, the long-term safety of using retroviral vectors to deliver genetic payloads to T cells is also apparent, helping offset earlier concerns about the procedure.
May 02, 2012
Only 1 in 5 People Living With HIV Fully Engaged in Care in U.S. Study Only one in five people living with HIV meet the criteria for being established and retained in care, according to a new analysis involving 12 clinics across the United States to be published in a forthcoming issue of the Journal of Acquired Immune Deficiency Syndromes. Though the authors warn that the data involving nearly 23,000 people enrolled in the HIV Research Network are not nationally representative, the results nevertheless underscore a need for improvements in keeping those living with the virus connected to care.
May 01, 2012
Reclast Boosts Bone Density for at Least Five Years in HIV Study Two annual doses of Reclast (zoledronate) improved bone health for up five years in a small study involving HIV-positive people with bone mineral deficiency, according to a study to be published by New Zealand researchers in the June issue of The Journal of Clinical Endocrinology & Metabolism (JCEM).
Facebook to Promote Organ Donation; May Benefit People With Hep C or HIV
Social networking giant Facebook has announced a plan to encourage its 161 million U.S. members to advertise their organ donor status in their profiles, according to The New York Times. The move may avert thousands of deaths in the United States among people waiting for transplants, including people with hepatitis C virus (HCV) and/or HIV infection.
More Treatment News
Have news about HIV? Send press releases, news tips and other announcements to firstname.lastname@example.org.